These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30677105)

  • 1. The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
    Reid TS; White J; Meneghini L
    J Fam Pract; 2019 Jan; 68(1 Suppl):. PubMed ID: 30677105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
    Arnolds S; Kuglin B; Kapitza C; Heise T
    Int J Clin Pract; 2010 Sep; 64(10):1415-24. PubMed ID: 20618882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.
    Vaidyanathan J; Wang YC; Tran D; Seo SK
    Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of non-standard insulin analogs for the treatment of diabetes mellitus.
    Pandyarajan V; Weiss MA
    Curr Diab Rep; 2012 Dec; 12(6):697-704. PubMed ID: 22983891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of basal insulins.
    Porcellati F; Bolli GB; Fanelli CG
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will the next generation of basal insulins offer clinical advantages?
    Garber AJ
    Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degludec: a novel basal insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec: a novel basal insulin analogue.
    Goldman-Levine JD; Patel DK; Schnee DM
    Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
    Owens DR
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.
    de la Peña A; Ma X; Reddy S; Ovalle F; Bergenstal RM; Jackson JA
    J Diabetes Sci Technol; 2014 Jul; 8(4):821-9. PubMed ID: 24876428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study.
    Li T; Liu H; Li S; Yu H; Li J; Tan H; Yu Y
    Clin Pharmacokinet; 2023 Mar; 62(3):449-456. PubMed ID: 36738401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New generation of insulins: glargine U300. Summary of clinical evidence].
    Musso C; Capurro L; Mingote E; Forti L; Guaita MS
    Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrated insulins in current clinical practice.
    Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
    Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.